Earnings Call · Q3 FY2025·2025-11-10

Q3 25EPS +100.00%*·Rev n/aQ2 25EPS +100.00%*·Rev n/aQ1 25EPS +100.00%*·Rev n/aQ4 24EPS -33.33%·Rev n/a⚠ consensus missing

Akebia Therapeutics, Inc. AKBA

Mercedes Carrasco — Senior Director

John Butler — Chief Executive Officer

Nicholas Grund — Chief Commercial Officer

Erik Ostrowski — Chief Financial Officer

−18.1%1d on move date−19.7% vs SPY3d−9.3%5d−18.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AKBA calls or request research access.

More AKBA calls Browse calls Request research access